B-001 is under clinical development by Shanghai Pharmaceutical Group and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for B-Cell Non-Hodgkin Lymphoma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how B-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

B-001 overview

B-001 is under development for the treatment of CD20 positive relapsed and refractory B-cell non-Hodgkin lymphoma, B-cell chronic lymphocytic leukemia, relapsed/refractory CD20-positive B-cell non-Hodgkin’s lymphoma, small lymphocytic lymphoma, neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis. It is administered through intravenous injection and subcutaneous. The therapeutic candidate is a recombinant humanized monoclonal antibody targeting B-lymphocyte antigen CD20 (CD20).

Shanghai Pharmaceutical Group overview

Shanghai Pharmaceutical (Group) Co., Ltd (SPGCL) is a pharmaceuticals and healthcare service provider, based in China. The company’s products portfolio includes active pharmaceutical ingredients, alexipharmic, alimentary tract and metabolism, anaesthetic, anti-allergic drugs, medicines: antibiotics, prescription drugs, traditional Chinese medicines and over the counter drugs. It markets its drugs in 30 countries from five foreign offices. The company’s research and development facility, central research institute, operates 10 centers across China. It operates as a subsidiary of Shanghai Industrial Investment (Holdings) Co. Ltd. SPGCL is headquartered in Shanghai, China.

For a complete picture of B-001’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.